

# Pertuzumab with trastuzumab and docetaxel for treating HER2-positive breast cancer

Information for the public

Published: 7 March 2018

[www.nice.org.uk](http://www.nice.org.uk)

Pertuzumab (Perjeta), with trastuzumab and docetaxel, is available on the NHS. It is a possible option for adults who have locally recurrent or metastatic (secondary) breast cancer that:

- is human epidermal growth factor receptor 2 (HER2)-positive
- cannot be removed by surgery and
- has not been treated with chemotherapy or targeted HER2 therapy before.

## Is this treatment right for me?

Your healthcare professionals should give you clear information, talk with you about your options and listen carefully to your views and concerns. Your family can be involved too, if you wish. Read more about [making decisions about your care](#).

## Questions to think about

- How well does it work compared with other treatments?
- What are the risks or side effects? How likely are they?
- How will the treatment affect my day-to-day life?
- What happens if the treatment does not work?
- What happens if I do not want to have treatment? Are there other treatments available?

## Information and support

NHS Choices may be a good place to find out more about breast cancer in [women](#) and [men](#).

These organisations can give you advice and support:

- [Breast Cancer Now](#), 0333 207 0300
- [Breast Cancer Care](#), 0808 800 6000
- [Macmillan Cancer Support](#), 0808 808 0000
- [Cancer Research UK Patient Information](#) (previously CancerHelp UK), 0808 800 4040

You can also get support from your local [Healthwatch](#).

NICE is not responsible for the quality or accuracy of any information or advice provided by these organisations.

ISBN: 978-1-4731-2466-0